This is a long term play on stem cells having a place in the mainstream health and wellness industry. Currently it’s a boutique option and not widespread. The growth we all want is based on this being widespread which comes with time. The RMAT possibility would have fast tracked this growth but If you believe stem cells will gain popularity and regulations will break down over time then how can one not see this as a bargain investment. The days of flipping this are temporarily over since they temporarily stopped the pursuit of RMAT. Only upside from here with increasing revenues and exclusive rights to a propriety method (kits)that a large number of the clinics in this space seem to have embraced. As the space grows so does USRM, The financials have improved and should continue to improve, the PPS may not reflect this but Comella and Tomas have the commitment and resilience to grow this space and along the way fight the FDA and put them in their place! That was a major step, which shows even the FDA can’t hold back stem cells. Newsflash!! The FDA seems to have backed off and next should need to open doors due to compelling results and public demand! Not much talk about the fact the FDA backed off, however this is a major milestone. Sure it isn’t RMAT but it is a big step in the right direction! We all saw what happened during RMAT when there was a chance to get “fast track” approval. RMAT is still on the table and we may very will get it in due time, however if it’s a slow track to the same levels RMAT PPS reached then this sure looks opportunistic! Btw the financials were not nearly as good as they are now back during the RMAT days so if you consider better financials coupled with long term acceptance and potential RMAT designation = dollar land in my opinion. Just my opinions but I do play cards weekly with very smart people from time to time!
